LEXINGTON, Mass., Jan. 18 /PRNewswire/ -- Genta Incorporated
(Nasdaq: GNTA) today announced the election of Dr. Daniel D. Von Hoff, a
distinguished cancer specialist, to its Board of Directors, effective January
12, 2000. Dr. Von Hoff is Professor of Medicine and Director of the
University of Arizona Cancer Center. He is also the current President of the
American Association for Cancer Research (AACR), the world's leading
scientific organization in this field.
"I have known Dr. Von Hoff for a number of years, and regard him as the
world's leading expert in oncology drug development," said Dr. Raymond P.
Warrell, Jr., Genta's President and CEO. "I am personally delighted by his
election to the Board. Genta will benefit enormously from his unparalleled
expertise as we enter the pivotal development stages for our lead compound,
G3139, as well as its successors."
"Having consulted for Genta in the past," said Dr. Von Hoff, "I am very
pleased to be advising the company again in this new capacity. I am very
familiar with G3139, which represents an exciting and highly innovative
approach to improve the effectiveness of cancer treatment. Successful
development of this agent may prove to be a major advance in patient care, and
I look forward to assisting Genta in this endeavor."
Genta is currently conducting clinical studies of G3139 in several types
of cancer, including malignant melanoma, prostate and breast cancers, and
non-Hodgkin's lymphoma. Together with a Cooperative Research and Development
Agreement (CRADA) with the U.S. National Cancer Institute, Genta has recently
initiated trials in patients with small cell lung cancer, colo-rectal cancer,
and acute myelocytic leukemia. The FDA recently granted Fast Track
designation for G3139 when used in combination with dacarbazine for treatment
of patients with advanced malignant melanoma. In developing its clinical
program, Genta has focused upon using G3139 in combination with major cancer
chemotherapeutic compounds, including docetaxel (Taxotere(TM); Aventis),
paclitaxel (Taxol(TM); Bristol Myers Squibb), irinotecan (Camptosar(TM);
Pharmacia Upjohn), and other agents.
G3139 was designed to reduce the Bcl-2 protein level in cancer through an
"antisense" mechanism that specifically targets the messenger-RNA produced by
the bcl-2 gene. In many human cancers, the Bcl-2 protein is believed to be a
major factor in inhibiting apoptosis, or programmed cell death. Bcl-2 is
believed to contribute to both inherent and acquired resistance to treatment
with anticancer drugs.
Following is a biography of Dr. Daniel D. Von Hoff M.D.:
Dr. Von Hoff graduated cum laude from Carroll College and received a M.D.
from Columbia University College of Physicians and Surgeons. After internship
and residency in internal medicine at the University of California, San
Francisco, he completed a medical oncology fellowship at the National Cancer
Institute. Dr. Von Hoff then moved to the University of Texas at San Antonio,
where he rose to Professor in the Department of Medicine and the Department of
Cellular and Structural Biology. In 1999, he became Director of the Cancer
Center and Professor of Medicine at the University of Arizona. Among numerous
awards, he has received the Frederick S. Philips Lectureship from Memorial
Sloan-Kettering Cancer Center, the Michel Clavel Lectureship from the European
Organization for Research and Treatment of Cancer (EORTC), and the Bagshawe
Lectureship from the British Association for Cancer Research. In 1997, Dr.
Von Hoff received the Richard and Hilda Rosenthal Foundation Award from AACR
and was elected President of that organization for 1999-2000. He has been an
editor of the journal, Investigational New Drugs, associate editor of Cancer
Research and Clinical Cancer Research, and has served on the editorial boards
of the American Journal of Medicine, Anticancer Drugs, Oncology, Annals of
Oncology, and nine other scientific journals. He is a Fellow of the American
College of Physicians, and has been a member of the Board of Directors of the
American Society of Clinical Oncology (ASCO) and AACR, as well as a member of
the FDA's Oncology Drug Advisory Committee (ODAC).
In 1989, Dr. Von Hoff became the Founding Director of the Institute for
Drug Development at the Cancer Therapy and Research Center in San Antonio. In
part, this activity was used to rapidly facilitate the translation of exciting
laboratory scientific advances into clinical research and patient care. In
his positions, he has participated in the early clinical investigations of
most of the new agents that have been approved for cancer treatment in the
United States over the past 20 years, including gemcitabine, docetaxel,
paclitaxel, topotecan, irinotecan, fludarabine, mitoxantrone, and dexrazoxone.
He has published more than 450 papers, 120 book chapters, 750 abstracts, and
several patents, primarily related to studies of new anticancer treatments.
Dr. Von Hoff has also served as a key scientific advisor to a number of
pharmaceutical and biotechnology companies. He is a founder and co-chair of
the Scientific Advisory Board of Ilex Oncology.
Genta Incorporated is a biopharmaceutical company whose strategy consists
of building a product and technology portfolio concentrating on cancer therapy
including its Anticode(TM) (antisense) products intended to treat cancer at
its genetic source. For more detailed information about Genta, please visit
our web site at www.Genta.com . To receive Genta Incorporated's
latest news release and other corporate documents via fax, at no cost, dial
1-800-PRO-INFO; use the Company's symbol GNTA. Or visit The Financial
Relations Board's web site at www.frbinc.com .
The statements contained in this press release that are not historical are
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, including statements regarding the expectations, beliefs,
intentions or strategies regarding the future. Without limiting the
foregoing, the words "anticipates," "believes," "expects," "intends," "may"
and "plans" and similar expressions are intended to identify forward-looking
statements. The Company intends that all forward-looking statements be
subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements reflect the Company's
views as of the date they are made with respect to future events, but are
subject to many risks and uncertainties, which could cause the actual results
of the Company to differ materially from any future results expressed or
implied by such forward-looking statements. For example, the results obtained
in pre-clinical or clinical studies reported above may not be indicative of
results that will be obtained in future clinical trials; Genta has not
successfully completed human clinical trials of a product based on antisense
technology; and delays in the completion of clinical trials as a result of
delays in patient enrollment or other factors may occur. Examples of such
risks and uncertainties also include, but are not limited to: the obtaining of
sufficient financing to maintain the Company's planned operations; the timely
development, receipt of necessary regulatory approvals and acceptance of new
products; the successful application of the Company's technology to produce
new products; the obtaining of proprietary protection for any such technology
and products; the impact of competitive products and pricing and reimbursement
policies; and the changing of market conditions. The Company does not
undertake to update forward-looking statements.
SOURCE Genta Incorporated